This study used Poisson regression modelling to estimate influenzaassociated mortality in New Zealand for 1990-2008. Inputs were weekly numbers of deaths and influenza and RSV isolates. Seasonal influenza was associated with an average of 401 medical deaths annually from 1990 to 2008, a rate of 10Á6 (95% CI: 7Á9, 13Á3) per 100 000 persons per year, which is 17 times higher than recorded influenza deaths. The majority (86%) of deaths occurred in those 65 years and over. There was no clear decline in influenza-associated mortality in this age group over the course of the study period.
Background
Standard mortality statistics markedly under-estimate influenza-associated deaths. Diagnosis of influenza's role in precipitating important secondary events (e.g. myocardial infarctions) can be difficult. 1 This leads to under-diagnosis of influenza as a contributor to morbidity and mortality. Such under-ascertainment is compounded by reporting practices for cause of death, which favour recording chronic diseases as the underlying cause. 2 Several statistical modelling techniques have been developed to overcome the challenges above (see Thompson et al 3 for a review). Poisson regression models (used in this study) incorporate virological data on the circulation of influenza [and other viruses, such as respiratory syncytial virus (RSV)], and can also account for excess mortality beyond seasonal variation.
New Zealand's only previous influenza mortality estimate was based on Poisson modelling for 1980-1992, which produced an estimated average of over 400 influenza-associated deaths per year. 4, 5 New Zealand requires updated information to better inform influenza prevention strategies and to supply a southern hemisphere perspective on the epidemiology and impact of influenza.
Methods

Data sources
Weekly mortality counts for New Zealand from 1990 to 2008 were obtained from the Mortality Collection (a comprehensive data set maintained by the Ministry of Health). Underlying cause of death (based on ICD code) was used to classify deaths into two groups treated independently for subsequent analysis: respiratory and circulatory deaths (ICD-9 390-519; ICD-10 I00-I99 and J00-J99); and all cause medical deaths (ICD-9 000-629, 680-739, 780-799; ICD-10 A00-N99, R00-R099; excluding mortality associated with pregnancy/childbirth, perinatal conditions and injuries.)
Population data from the New Zealand Census of Population and Dwellings (Statistics New Zealand) in 1991, 1996, 2001 and 2006 gave NZ population counts for every week in the study period (using linear interpolation and extrapolation for the more recent period). The log of these counts was used as an offset variable in the Poisson regression models.
Weekly counts of influenza A, influenza B and RSV in New Zealand were obtained from the Weekly Virology Reports [Environmental Science and Research (ESR)]. These counts combine data on positive isolates from (i) influenza sentinel surveillance in general practices (collected May to September each year) and (ii) regional laboratories (mostly hospital patients, covering the entire year). RSV isolates are identified by ESR and hospital laboratories from specimens received throughout the year.
Model
For each cause of death category (respiratory and circulatory; all medical) and age grouping (all ages; under 65; 65 plus), we created independent Poisson regression equations that provided the best fit of the observed pattern of 
where subscript i is week number; Y i the output of the modelling process for that week (predicted mortality count); a is the population offset (accounts for population size changes over time); and t i represents number of weeks since the start of the modelling period. For the estimated regression parameters, b 0 is the intercept (number of deaths predicted at t 0 , in the hypothetical absence of any influenza virus); b 1 (t i ) models linear trend and b 2 (t i 2 ) models quadratic trend in mortality over time. Seasonal fluctuations in deaths are modelled with the cyclical parameters b 3 [sin From this fitted equation, we calculated for each week the number of predicted deaths, when first the influenza A term and then the influenza B term were set to zero. This provided the number of deaths expected in the absence of both influenza A and B. These weekly totals were summed to provide yearly estimates of influenza-associated deaths.
Mean number of influenza-associated deaths was calculated across all study year estimates, with 95% confidence intervals for the overall estimate calculated using the standard error of these mean counts (t-distribution) -results are expressed as mortality rates per 100 000 population. Confidence intervals for annual rates (Tables 2, 3) were calculated on a log scale, using the yearly sum of excess deaths as a Poisson variable (p. 80). 7 Results Table 1 summarises the yearly counts of influenza A, influenza B and RSV isolates used in the regression model, along with the observed number of deaths due to respiratory and circulatory causes, and all medical causes. Figure 1 presents the seasonal mortality component of the model for those aged 65 plus (seasonal pattern as solid line; weekly observed all-cause medical mortality as circles).
Based on respiratory and circulatory mortality, there were on average 305Á8 influenza-associated deaths per year (95% CI: 235Á2, 376Á3). This is a rate of 8Á1 deaths per 100 000 persons (95% CI: 6Á3, 9Á9 per 100 000) ( Table 2) . Mortality varied by study year and age group with 89Á4% of deaths in those 65 plus years of age. For all medical cause mortality (Table 3) , there were on average 400Á5 influenza-associated deaths per year (95% CI: 294Á3, 506Á6). This is a rate of 10Á6 deaths per 100 000 persons (95% CI: 7Á9, 13Á3). Mortality varied by study year and age group with 86Á2% of deaths in those 65 plus years of age.
Our mean estimates of influenza-associated deaths are 13 or 17 times higher than the number explicitly recorded as due to influenza in the Mortality Collection (mean of 23Á4 deaths per annum; range: 2-95; see Table 4 ).
Influenza mortality was highest in years dominated by influenza A(H3N2) compared with influenza A(H1N1) and influenza B (Figure 2 ).
Discussion
This study estimates an average of 306-401 influenzaassociated deaths per year in New Zealand (the lower estimate from modelled respiratory and circulatory deaths; the upper estimate from all medical deaths). Influenza was associated with 2Á2% of respiratory and circulatory deaths and 1Á6% of all medical deaths. As expected, the majority of influenza-associated deaths were in those aged 65 plus.
Annual modelled estimates varied considerably, from 31 influenza-associated deaths in 1991 to 898 in 2003. The variability of the impact of seasonal influenza appeared to be influenced by the dominant circulating influenza virus. These estimates also demonstrate the limitations of influenza diagnosis, with an average of only 23 influenza deaths per year recorded in the Mortality Collection. This study's estimates are broadly comparable with previous estimates for New Zealand and other developed countries. The average estimate (all medical cause data) is lower than the previous New Zealand study estimate of around 490 deaths per year. 4 For those aged 65 plus in New Zealand, the average rate of 61Á0 influenza-associated deaths per 100 000 persons (respiratory and circulatory data analysis) is similar to the corresponding estimate of 66Á1 deaths per 100 000 in the USA. Poisson modelling enabled the use of robust influenza circulation data in mortality estimates. We reduced the influence of circulating RSV on our estimates, yielding a better model fit (under 65: no RSV AIC = 7512; RSV model AIC = 7362; aged 65+, no RSV model AIC = 9913; RSV model = 9318). The Poisson model is limited by an inability to account for interconnectedness between influenza deaths, such as during seasonal epidemics; use of a log-link has been criticised as inappropriate for influenza modelling, although results appear similar to using a linearlink. 9 As influenza A specimen subtyping was incomplete, we cannot account for different effects of H1N1 and H3N2 on mortality. Furthermore, total numbers of tested specimens were not available as a denominator, so we cannot fully account for influences of increased testing rates over time. Positive specimen counts will also be influenced by commencement of sentinel surveillance in 1991 and diag- nostic introduction of rapid antigen testing and PCR during the study period. However, specimen counts have been used previously in Poisson modelling, where mortality patterns were similar by age and time to Serfling estimates. 10 It would be valuable to apply the Poisson model to hospitalisation data to estimate the serious morbidity caused by influenza. The larger number of hospitalisation events would allow us to estimate inequalities by ethnicity and other sociodemographic factors. There are significant health disparities in New Zealand; M aori and Pacific peoples have higher rates of hospitalisation for infectious diseases, 11 including both seasonal 12 and pandemic 13 influenza. These results show the large public health impact of influenza and the variability in mortality between years. Our estimates do not indicate a clear decline in influenzaassociated mortality over this period.
In summary, this study demonstrates the continued impact of influenza on population health in New Zealand: this evidence will better equip public health policy makers to review current influenza strategies and to identify additional actions to effectively tackle this persistent and important global health concern.
